Tongteng Xinchuang and ETOWN BIO Public Technology Service Platform will work together to build a laboratory. With the laboratory as the platform, both parties will gather advantageous resources, integrate scientific research capabilities, strengthen technological exchange and cooperation, and promote the research and industrialization process of biological products.

This collaboration not only covers the entire process of services from cell line construction to scaling up adherent cells, but we will also provide customers with a one-stop solution. This not only helps to improve product development efficiency and reduce costs, but also provides customers with more comprehensive and professional solutions.

With the self-developed and produced CEL-G? by Tongteng Xinchuang; The official entry of Culture Ad60 series fixed bed bioreactors into the ETOWN BIO public technology service platform marks a substantial step in the cooperation between the two parties. CEL-G® The Culture Ad60 series fixed bed bioreactor is suitable for large-scale cGMP grade virus production. Its unique technology provides a low shear 3D culture environment for cell growth, covering the entire process from process parameter development, pilot clinical trials to large-scale commercial production, achieving excellent cell growth and high virus production. Therefore, it has broad application prospects in the field of biomedicine.

We believe that Tongteng Xinchuang and ETOWN BIO public technology service platform will work hand in hand to achieve more breakthroughs and achievements in the field of biomedicine. This will also bring more innovative achievements to the industry and ultimately benefit customers and the general public.

In future cooperation, Tongteng Xinchuang and ETOWN BIO public technology service platforms will fully leverage their respective advantages in the field of biopharmaceuticals, engage in in-depth cooperation in cell line construction, scaling up adherent cells, and provide customized services to customers. At the same time, both sides will strengthen communication and collaboration in scientific research and technological exchange, and jointly explore the possibility of applying cutting-edge technology to the field of biomedicine.

If you are interested in our one-stop full process service, please feel free to contact the sales manager of Tongteng Xinchuang at any time. We will wholeheartedly provide you with the most professional and thoughtful service, ensuring that you receive maximum convenience and satisfaction during the cooperation process. Looking forward to working together with you to create a better future!

Contact: Manager Bao

Phone：18731609924

Tongteng Xinchuang (Suzhou) Technology Co., Ltd. is a wholly-owned subsidiary of Shanghai Tongteng Biotechnology Co., Ltd. The company has a 2200 square meter production factory in Taicang, Jiangsu, equipped with professional research and development laboratories, production workshops, quality inspection departments, and finished product warehouses. Our company develops and produces industrial grade fully automatic fixed bed bioreactors and related supporting equipment and consumables, providing high-quality localized cell research and production solutions for cell and gene therapy, antibody and vaccine production enterprises. The company adheres to the business philosophy of "integrity, focus, professionalism, and efficiency" and aims to become an advanced equipment manufacturer and technology solution provider in the field of biopharmaceutical research and production.

The ETOWN BIO public technology service platform is located in Beijing Yizhuang Biomedical Park, Beijing Economic and Technological Development Zone, with a total area of 8000 square meters. It has nearly 2000 experimental instruments and equipment and a high-level professional technical team. It can provide enterprises with various services such as inspection and testing, process development, pilot production, animal foster care, cell and gene therapy technology services, industry forums and training. In addition, the platform's inspection and testing services have CMA and CNAS testing qualifications. The platform is committed to building a full chain biopharmaceutical public technology service platform, providing common and key technology services for biopharmaceutical enterprises, and contributing to the development of a global "new drug intelligent manufacturing" industry highland in the Economic